Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: David T. letter posted as a courtesy to David T

David T. letter posted as a courtesy to David T

posted on Dec 19, 2006 01:31AM

My views of Patriots News Release: (written Dec, 10th, after last news release)

1. While it is exciting to see ongoing licensees signing up through no efforts of PTSC, I do not feel we have any qualified BOD's or a CEO with any business experience sufficient to guide us forward (acquisitions) at this point.  PTSC's history dictates that record.

I feel the smartest thing for us to do at this point is to "sit tight" until after the law suit is over.

In the meantime future revenues should be divided up as follows:

1. 25% to share buyback  2. 25% for dividends  3. 50% liquid assets.  No more talk of acquisitions, it appears to have a negative view to the market.  These above percentages should be announced after each and every new signing, thereby creating our own PR.  These  views are shared by several large PTSC shareholders. 

Shareholders names provided upon request. Any shareholders interested in voting in a block you may write jbonner@tampabay.rr.com

Best regards,

David T 

PS we are long and feel PTSC has fantastic potential and is currently very under-priced.

 

Share
New Message
Please login to post a reply